Scancell says it is working closely with US regulators ahead of phase II study of cancer immunotherapy The UK group is planning to use its SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma. [View article] Wednesday 24 October 2018 10:40 Categories: Media Coverage SCIB1 Year - 2018
Scancell Holdings part of the new cancer revolution The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology. [View article] Tuesday 25 September 2018 13:20 Categories: Immunobody Media Coverage Modi-1 Moditope SCIB1 SCIB2 Year - 2018
2018 Preliminary Results To download click here Tuesday 25 September 2018 13:00 Categories: Immunobody Modi-1 Moditope News Regulatory News SCIB1 Year - 2018
Board Change To download click here Friday 10 August 2018 13:00 Categories: News Regulatory News Year - 2018
Scancell Holdings extends collaboration with Sweden's Karolinska Institute The company first teamed up with Sweden's world-leading medical research university two years ago [View article] Thursday 9 August 2018 13:15 Categories: Media Coverage Moditope Year - 2018
Extension of Karolinska research collaboration To download click here Thursday 9 August 2018 13:00 Categories: Moditope News Regulatory News Year - 2018
PDMR Dealing To download click here Wednesday 25 July 2018 13:00 Categories: News Regulatory News Year - 2018
Issue of Equity to Ichor To download click here Tuesday 24 July 2018 13:00 Categories: News Regulatory News Year - 2018
Scancell exercises TriGrid worldwide commercial option from Ichor To download click here Wednesday 18 July 2018 13:00 Categories: Immunobody News Regulatory News SCIB1 Year - 2018
Scancell Holdings inks drug delivery technology deal It has exercised an option on TriGrid, which was developed by Ichor Medical Systems [View article] Wednesday 18 July 2018 11:09 Categories: Media Coverage SCIB1 Year - 2018